Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
- Category: Proteins and Peptides
- Published on Monday, 11 December 2017 15:21
- Hits: 809
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours
Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing
SOUTH SAN FRANCISCO, CA, USA I December 11, 2017 I Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced interim Phase 1/2 data on its subcutaneously administered, prophylactic Factor IX variant CB 2679d/ISU304 in an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition held on Dec. 9-12, 2017 in Atlanta. The data demonstrate that subcutaneous delivery of CB 2679d significantly increases the factor IX (FIX) activity half-life to 98.7 hours.
Dr. Howard Levy, chief medical officer of Catalyst, presented results from the first three cohorts of the Phase 1/2 trial of CB 2679d in patients with severe hemophilia B. During these first three cohorts, patients received single intravenous (IV) and subcutaneous (SQ) doses of CB 2679d. Results from cohort 1, which compared 75 IU/kg IV CB 2679d with 75 IU/kg IV BeneFIX, showed that IV CB 2679d is approximately 22 times more potent and has a significantly longer half-life (27 vs 21 hours, p = 0.0014) and mean residence time than BeneFIX (36 hours vs 25 hours, p = 0.00004). Cohorts 2 and 3 compared 75 IU/kg IV CB 2679d with 75 IU/kg and 150 IU/kg SQ CB 2679d respectively. These results showed that SQ delivery of CB 2679d had a bioavailability of 18.5% and significantly increases the FIX activity half-life to 98.7 hours vs 27.6 hours for a IV dose of 75 IU/kg, (p = 0.005). No serious adverse events were observed. The data to date support the potential of achieving normal FIX levels in individuals with hemophilia B with daily or less frequent subcutaneous dosing.
“The results from these first three cohorts demonstrate the promise of CB 2679d as a safe prophylactic treatment for patients with hemophilia B,” said Dr. Levy. “The significantly increased half-life of CB 2679d and bioavailability after subcutaneous dosing suggests that CB 2679d may provide superior prophylaxis capabilities compared with intravenous extended half-life agents, with the potential to normalize FIX levels. We eagerly await the results from daily subcutaneous doses of CB 2679d on Factor IX blood levels that are expected in early 2018.”
About the Phase 1/2 Trial
CB 2679d is designed as a best-in-class high potency recombinant Factor IX product. The Phase 1/2 clinical trial of CB 2679d in patients with severe hemophilia B is being conducted at three centers in South Korea by the Company’s collaborator, ISU Abxis, which uses ISU304 as an alternate product name. The trial aims to measure the subcutaneous bioavailability and clotting ability of CB 2679d achieved after single intravenous and subcutaneous dosing in the first four cohorts, followed by daily subcutaneous injections of CB 2679d in the fifth, and final, cohort. In June 2017, the European Commission and in September 2017, the U.S. Food and Drug Administration (FDA) granted orphan drug designations for CB 2679d. Complete trial results are expected in early 2018.
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit http://www.catalystbiosciences.com/.
SOURCE: Catalyst Biosciences